Ansell Limited (ANN.AX) - Deep Dive Research Report

Prepared 25 June 2026. Ansell reports on a 30 June fiscal year and discloses results half-yearly, so the six reporting periods used throughout are FY23 (Aug 2023), 1H FY24 (Feb 2024), FY24 (Aug 2024), 1H FY25 (Feb 2025), FY25 (Aug 2025) and 1H FY26 (Feb 2026). The most recent, 1H FY26, was released on 16 February 2026; the next scheduled report (FY26 full year) is not due until August 2026, so the latest call is roughly four months old simply because no newer one exists.

1. What the Company Does

Ansell makes the gloves and protective gear that people wear to keep their hands and bodies safe at work. A surgeon scrubbing in, a chemical-plant operator handling solvents, a cleanroom technician assembling microchips, a worker on an oil rig swinging steel - all of them may be wearing Ansell product. The company designs, manufactures and sells personal protective equipment (PPE), with hand protection at its core, to two broad worlds: healthcare and industry. Roughly 10 million workers in more than 100 countries put on an Ansell-branded product on any given day.

The business is much older than its current shape. It traces to 1905, when Eric Ansell, a former Dunlop employee, set up the Ansell Rubber Company in Melbourne dipping rubber into latex products - originally condoms and balloons. For most of the twentieth century Ansell sat inside the Pacific Dunlop industrial conglomerate, and for decades it was as much a sexual-wellness company as a glove company. The pivotal decision that defines today's Ansell came in 2017, when management sold the condom and sexual-wellness business (the LifeStyles brand) for about US$600 million to focus exclusively on protection. From that point Ansell became a pure-play maker of industrial and medical gloves and PPE, and every strategic move since has been about deepening that focus.

The second defining move was the July 2024 acquisition of Kimberly-Clark's PPE business (internally renamed "KBU") for US$638.9 million. That deal pulled in the KleenGuard industrial-PPE brand and the Kimtech scientific/cleanroom brand, bolting volume and shelf space onto both of Ansell's existing segments in one step. The Ansell of 2026 is therefore a focused, vertically integrated PPE manufacturer that recently doubled down via a large bolt-on acquisition, all while managing a CEO succession (long-serving Neil Salmon retiring, former Metso chief executive Nathalie Ahlström taking over in early 2026).

The technical heart of the business is harder than it looks. A high-end industrial glove has to stop a cut without sacrificing the dexterity to pick up a screw, resist a specific chemical for a measured number of minutes, and survive thousands of grip cycles. A surgical glove must be sterile, biocompatible, puncture-resistant, and thin enough that a surgeon can feel a suture - and it has to pass medical-device regulatory approval in every market it enters. Ansell's defensibility comes from a century of polymer and dipping process knowledge, an owned manufacturing base across low-cost Asian geographies, and a wall of certifications and approvals that a new entrant cannot replicate quickly.

A concrete example: when an auto-parts manufacturer wants to cut hand injuries on an assembly line, Ansell does not just sell a box of gloves. Its "Ansell Guardian" service audits the plant's tasks, identifies where workers are exposed to cuts, abrasion, oil or impact, recommends specific HyFlex or Ringers SKUs for each station, and tracks the reduction in recordable injuries and glove spend afterward. The glove becomes embedded in the customer's safety program, which is exactly why the customer is slow to switch.

2. Business Segments

Ansell runs two Global Business Units (GBUs): Healthcare and Industrial. They share manufacturing know-how and a global footprint but serve different buyers, sit under different regulatory regimes, and have different economics.

Healthcare

The Healthcare segment makes surgical gloves, examination and single-use gloves, life-sciences/cleanroom gloves and garments, and related consumables for hospitals, surgical centres, dental and veterinary practices, and - increasingly important - pharmaceutical and life-sciences manufacturing. Core brands include GAMMEX and ENCORE (surgical), MICRO-TOUCH and MICROFLEX (exam/single-use), BioClean (cleanroom), and, since the KBU deal, Kimtech (scientific and cleanroom).

The core capability here is regulatory and biocompatibility expertise layered on top of high-volume dipping. A surgical glove is a Class II medical device; getting a new formulation (for example Ansell's non-latex SENSOPRENE surgical glove) approved across the US, EU and Asia is a multi-year process. The Life Sciences sub-segment - cleanroom gloves and garments for pharma and semiconductor fabs - is the most attractive part: it sells into validated, audited production environments where a customer cannot casually swap suppliers because the glove is written into the customer's own quality documentation.

Within Healthcare, Ansell competes against Asian disposable-glove volume producers (Top Glove, Hartalega, Kossan, Supermax) at the commodity exam end, and against Cardinal Health, Mölnlycke and Medline at the branded surgical end. It wins on brand, surgical specialisation and life-sciences depth; it loses, by design, on bulk commodity exam gloves where Malaysian producers compete purely on price. Ansell holds roughly a 13% share of the medical-glove market. Management frames Healthcare as the larger of the two GBUs and the segment most leveraged to the structural growth of pharma and surgical procedure volumes - but also the segment that took the most pain in the 2022-2024 destocking cycle.

Industrial

The Industrial segment makes hand and body protection for manufacturing, automotive, chemical, metal fabrication, mining, oil and gas, construction, food, utilities and first responders. Core brands include HyFlex (mechanical/cut protection - the flagship), Ringers (impact protection, strong in oil and gas), AlphaTec (chemical protection suits and gloves), ActivArmr (military and heavy-duty), TouchNTuff (single-use industrial), EDGE (value tier), and KleenGuard (industrial coveralls and PPE, acquired with KBU).

The core capability is engineered performance: combining yarn engineering, polymer coatings and ergonomic design so a single glove can deliver a measured cut-resistance rating, oil grip, and all-day comfort. Ansell's R-840 impact glove (Ringers) was described by management as its "most successful ever new product," illustrating how a single well-engineered SKU can drive segment growth. Industrial sells through safety distributors and increasingly through the Ansell Guardian advisory model described above.

Within Industrial, the named competitors are different: Honeywell and 3M (diversified industrial-safety giants), Superior Glove, Protective Industrial Products (PIP), MCR Safety and Showa, alongside private-label and regional players. Ansell wins on its breadth of engineered SKUs, the Guardian service, and brand trust in safety-critical applications; it is more exposed where buyers treat gloves as a commodity. Ansell holds roughly a 10.5% share of the industrial safety-gloves market. Management has consistently treated Industrial as the margin and reliability engine - Industrial EBIT margin reached an all-time high of 16.5% in FY24 - while pointing to three organic growth levers: emerging-market expansion, new-product innovation, and channel partnerships.

Segment summary

3. Products and Business Detail

Ansell's catalogue is organised around branded product families, each aimed at a specific hazard:

• HyFlex - the flagship industrial line. Coated, knitted gloves engineered for cut, abrasion and oil grip with high dexterity. The 2026 "HyFlex Precision Comfort" series with Aerofit technology shows the continuous incremental innovation in this line. Bought by manufacturing and automotive plants.
• Ringers - impact-protection gloves (the R-840 is the standout), heavily used in oil, gas and heavy industry where back-of-hand impact injuries are common.
• AlphaTec - chemical-protection gloves and full suits, sold to chemical plants, petrochemicals and hazardous-materials handlers; the performance claim is measured permeation breakthrough time against specific chemicals.
• TouchNTuff - single-use industrial gloves with chemical splash resistance. The 2026 launch of the TouchNTuff 93-800, marketed as the first disposable glove with at least 15 minutes of acetone resistance, is a typical example of a niche performance claim that commands a price premium.
• GAMMEX / ENCORE - surgical gloves, including non-latex SENSOPRENE formulations for latex-allergic environments.
• MICRO-TOUCH / MICROFLEX - examination and single-use gloves for clinical and lab use.
• BioClean / Kimtech - cleanroom gloves and garments for pharma and semiconductor controlled environments.
• KleenGuard - industrial coveralls and PPE acquired with KBU.
• ActivArmr (military/tactical), EDGE (value tier), MICRO-TOUCH, SANDEL (safety products) round out the range.

Certifications and process knowledge are the real product. Surgical and exam gloves are regulated medical devices requiring market-by-market approval; industrial gloves carry EN 388 (mechanical), EN 374 (chemical) and ANSI cut-level ratings that must be independently tested and certified. The manufacturing process - dipping ceramic hand formers into compounded latex, nitrile, neoprene or polyisoprene, then leaching, curing, coating and quality-testing - is capital-intensive and yield-sensitive, and the formulations are proprietary. This is why Ansell owns its plants rather than outsourcing: process control is the product.

Manufacturing spans low-cost Asian and select Western geographies - Malaysia, Sri Lanka, Thailand, Vietnam, China, India, plus Lithuania, Portugal, Mexico and Brazil - giving Ansell both cost competitiveness and a degree of geographic diversification that matters when US tariffs target specific countries of origin. The Accelerated Productivity Investment Program (APIP), running across the report window, has been consolidating this footprint, automating lines and reducing manufacturing headcount, with the annualised FY26 pre-tax savings target raised from US$45m to US$50m over the period.

The KBU acquisition (completed 1 July 2024) was the most significant recent milestone: it added the KleenGuard and Kimtech brands, expanded Ansell's position in North America, and required a roughly 12-month transitional-services period to migrate the business off Kimberly-Clark's systems - a migration management prioritised completing with zero customer disruption.

4. Customers

Ansell sells to two distinct buyer worlds, almost always through distribution rather than direct.

In Healthcare, the buyers are hospital procurement departments, group purchasing organisations (GPOs), distributors like Cardinal Health and Medline, and - for Life Sciences - the quality and procurement teams inside pharma and semiconductor manufacturers. The decision criteria differ sharply by sub-segment. For commodity exam gloves, price and availability dominate, which is why Ansell does not try to win there. For surgical and cleanroom products, the criteria are clinical performance, regulatory approval, and the fact that the glove is written into the customer's own validated processes. The sales cycle for a hospital system or a pharma cleanroom can run many months and involves clinical evaluation.

In Industrial, the buyer is typically a plant safety manager or an EHS (environment, health and safety) function, purchasing through industrial-safety distributors. The decision is driven by injury-reduction performance and total cost (a more durable glove that cuts injury claims can be cheaper despite a higher unit price). This is where the Ansell Guardian advisory model creates stickiness: once Ansell has audited a customer's tasks and embedded specific SKUs station-by-station, switching means re-running the whole safety assessment.

Switching costs are real but vary. They are highest in surgical, cleanroom and Guardian-managed industrial accounts (regulatory re-validation, clinical re-evaluation, re-auditing) and lowest in commodity single-use. Customer concentration is moderate - large distributors and GPOs aggregate demand, but no single end customer dominates the group. Contract structures are a mix of distributor supply agreements, GPO contracts and spot/distributor pull-through, which gives reasonable but not bond-like revenue predictability. The 2022-2024 episode showed the vulnerability: when distributors and hospitals over-ordered during COVID and then destocked, Ansell's reported sales swung hard even though end demand was relatively stable - a reminder that Ansell sells through inventory-holding channels, not directly to the worker.

5. Competitive Landscape

The protective-glove industry is moderately fragmented and splits into two tiers. Tier 1 is diversified global safety players selling engineered, branded, higher-margin product - Ansell, Honeywell and 3M. Tier 2 is the Southeast Asian volume machine - Top Glove, Hartalega, Kossan, Supermax, Sri Trang, Intco - that dominates commodity disposable gloves on cost. Ansell deliberately straddles the line: it competes in Tier 1 on engineered industrial and surgical product, while buying or sourcing commodity volume where it makes sense rather than trying to out-cost Malaysia.

Ansell wins against the Asian volume producers on brand, engineered performance, regulatory approvals and its Guardian service model; it cannot and does not try to beat them on commodity exam-glove price. Against Honeywell and 3M, Ansell competes as the more glove-focused specialist with a deeper hand-protection catalogue, while Honeywell and 3M bring vast diversified-industrial distribution and brand reach that dwarf Ansell's. Barriers to entry are meaningful at the top end (regulatory approvals, formulation IP, owned manufacturing, certification testing) and low at the commodity end (which is why that end is a price war). Ansell holds roughly 10.5% of industrial safety gloves and roughly 13% of medical gloves - leadership positions, but in a market where the top players together hold only a minority of total share.

(Malaysian glovemaker market caps are quoted only as an order-of-magnitude peer reference; their valuations were extremely volatile during a 2026 sector rally and should be treated as approximate.)

The structural shift to watch is the Asian disposable producers periodically attempting to move up-market into branded and industrial product, and the recurring boom-bust cycle in commodity glove pricing. Ansell's defence is to stay above the commodity fight, where its brand, approvals and service model give it pricing power the volume producers lack.

6. Industry

Demand for Ansell's products is driven by three forces: workplace-safety regulation (which mandates PPE), healthcare and pharmaceutical activity (surgical procedure volumes, drug manufacturing, cleanroom expansion), and general industrial production (the more manufacturing, mining and construction activity, the more gloves worn out and replaced). It is fundamentally a consumable - gloves are used and discarded - which gives the business a recurring-revenue character once channel inventories are normal.

The industrial safety-gloves market was valued at roughly US$7.1 billion in 2024 and is projected to reach around US$9.3 billion by 2030, a mid-single-digit (~4.6%) CAGR (Arizton / Grand View / Mordor estimates; broader "gloves" definitions that include all disposables run larger and faster-growing). Medical gloves are a separate, larger pool. Asia-Pacific is the fastest-growing region (industrialisation in China and India), while North America is the largest and most profitable market - which is precisely why the KBU acquisition, strong in North America, mattered.

In the global supply chain, Ansell sits as a manufacturer-brand owner: it makes most of its own product in Asia and sells worldwide, distinguishing it from pure traders and from the commodity producers who sell unbranded volume. Regulation is a structural tailwind and a moat - medical-device approvals, chemical-permeation and cut-resistance standards, and tightening workplace-safety rules all favour certified branded suppliers over uncertified imports.

The industry's defining cyclicality is the channel inventory cycle, brutally illustrated in 2021-2024: COVID drove massive over-ordering, then a multi-year destocking unwound it, depressing Ansell's reported sales even as end demand held up. Tariffs are the current live headwind - US tariffs on gloves imported from Southeast Asia prompted Ansell to pre-build inventory ahead of increases and to lean on pricing and productivity to offset the cost. Tailwinds: regulation, pharma/cleanroom growth, emerging-market industrialisation. Headwinds: commodity-price wars at the disposable end, tariff volatility, and raw-material (latex, nitrile feedstock) and freight inflation.

7. Growth Triggers

Drawn directly from the six reporting-period calls; each cited.

• KBU synergy delivery beginning FY26. Management stated cost synergies would not start until FY26 because of the transitional-services dependency, making FY26 the year integration benefits flow through. (FY24 concall, 20 Aug 2024)

  "Synergy delivery won't begin until F'26."

• KBU integration completion and exit of transitional service arrangements by end FY25, removing a cost drag and freeing the acquired business to run on Ansell systems. (1H FY25 concall, 10 Feb 2025; reaffirmed FY25 concall, 25 Aug 2025)
• APIP productivity savings ramping to US$50m annualised by FY26, with the target raised over the period (from US$45m). A repeated trigger across multiple calls. (1H FY24 concall, 20 Feb 2024; FY24 concall, 20 Aug 2024; 1H FY25 concall, 10 Feb 2025)
• New-product momentum led by the Ringers R-840 impact glove, described as the company's most successful new product ever, with significant growth expected. (FY24 concall, 20 Aug 2024)

  "Our most successful ever new product."

• Continued new-product launches into 2026 - HyFlex Precision Comfort (Aerofit), TouchNTuff 93-800 acetone-resistant disposable, and expanded sterile TouchNTuff lines - feeding the Industrial and Life Sciences pipelines. (Product launches around 1H FY26, Feb 2026)
• Three Industrial organic-growth levers - emerging-market investment, new-product innovation, and channel partnerships. (FY24 concall, 20 Aug 2024)
• End of the healthcare destocking cycle unlocking volume recovery, flagged as "substantially at the end" after more than two years, restoring underlying Healthcare growth. (FY24 concall, 20 Aug 2024)
• FY26 adjusted EPS guidance of roughly US137-149¢ maintained at the half, with double-digit earnings growth and margin expansion guided despite subdued end markets. (1H FY26 concall, 16 Feb 2026)

8. Key Risks

• Channel destocking / inventory whipsaw. Ansell sells through distributors, GPOs and hospitals that hold inventory, so a swing in their stocking behaviour moves Ansell's reported sales far more than end demand moves. The 2022-2024 destocking cut sales hard while workers kept using gloves at a steady rate. Mechanism: customers over-order in a scare, then run down inventory for years. This is a high-probability, recurring moderate drag rather than a one-off, and management spent four of the six calls in this window managing through it. The mirror-image risk now is the inventory Ansell itself pre-built ahead of tariffs, which must unwind cleanly.

• US tariffs on Southeast Asian-made gloves. Most of Ansell's product is made in Malaysia, Sri Lanka, Thailand and Vietnam and sold heavily into the US. New or rising US tariffs raise landed cost; if Ansell cannot fully recover that through price, margin compresses. Management explicitly built inventory ahead of tariff increases in 2H FY25 and is relying on pricing and productivity to offset. Moderate-probability, moderate-impact, and live.

• Commodity glove price wars. At the disposable/exam end, Malaysian volume producers compete on price through brutal boom-bust cycles. If oversupply collapses commodity pricing, Ansell's exam and single-use lines are squeezed. Ansell's defence is to stay above the commodity fight, but it is not immune at the margin.

• Raw-material and freight inflation. Latex and nitrile feedstock (oil-linked) and shipping costs feed directly into cost of goods. Management flagged a "single-digit million" raw-material and freight headwind for FY25 and noted Red Sea shipping disruption deferring surgical orders. A persistent moderate drag, partly hedged by pricing.

• Integration and execution risk on KBU. A US$638.9m acquisition that required a 12-month systems migration carries the risk of customer attrition during the cutover or synergies under-delivering. Management noted a "somewhat lower sales outcome" in 2H FY25 as customers positioned ahead of the cutover - exactly the kind of friction that can become a bigger problem if mishandled. Medium-probability, medium-impact; so far navigated.

• Leadership transition. A new CEO (Nathalie Ahlström) taking over from a long-serving chief in early 2026, mid-way through KBU integration and a tariff cycle, introduces strategy-continuity risk. Low-to-moderate probability of disruption, but worth watching given the timing.

9. Walk the Talk

Six reporting periods anchor this assessment: FY23 (Aug 2023), 1H FY24 (20 Feb 2024), FY24 (20 Aug 2024), 1H FY25 (10 Feb 2025), FY25 (25 Aug 2025) and 1H FY26 (16 Feb 2026).

The story begins in the trough. At FY23 (Aug 2023) management was cutting the dividend (to US45.9¢ total, an explicit 40% payout of depressed earnings) as destocking gutted Healthcare, particularly Life Sciences, which fell more than 25% organically. This was a credibility low point - but management was candid that the problem was channel inventory, not lost end demand, and framed it as a cycle that would unwind.

By 1H FY24 (Feb 2024) the productivity program became the proof point. Management raised the APIP annualised FY26 savings target from US$45m to US$50m and guided Healthcare to improve in 2H as surgical and life-sciences inventories normalised. They delivered on the productivity commitment in subsequent periods - APIP savings consistently tracked at or ahead of target, and management noted savings "ahead of original target" by FY24.

At FY24 (Aug 2024) management made several datable commitments: destocking was "substantially at the end"; FY25 adjusted EPS would land in US107-127¢; KBU (completed 1 July 2024) synergies would not begin until FY26; and the Ringers R-840 was the "most successful ever new product." These largely held. Destocking did fade. KBU was integrated on schedule.

By 1H FY25 (Feb 2025) the recovery was visibly real - Healthcare organic EBIT up 30%, Industrial up 12.2%, total organic sales up 12.5% - and management did something credible: they raised FY25 guidance, lifting the range to US118-128¢ and noting KBU was "ahead of expectations."

"FY25 Adjusted EPS guidance range was increased ... to US118¢ to US128¢."

At FY25 (Aug 2025) they delivered adjusted EPS of about US126¢ - at the top of the raised range - with organic sales up 7.7%, EBIT up 10.4% and margin up 200bps to 14.1%. They also announced a 10% on-market buyback, putting capital behind the confidence. That is a clean guide-raise-then-deliver sequence.

At 1H FY26 (Feb 2026), in subdued markets and mid-CEO-transition, management delivered double-digit underlying earnings growth and margin expansion, and maintained (not cut) FY26 guidance of roughly US137-149¢ adjusted EPS.

The pattern across the six periods is management that was honest at the bottom of the cycle, set conservative ranges, then raised and delivered as conditions improved. The clearest tell is FY25: guidance was raised at the half and the full-year result landed at the top of the raised range, followed by a buyback. This reads as a credible, slightly conservative management team that does roughly what it says - not a serial over-promiser. The one caveat is that much of the FY25 strength was cyclical recovery from a self-inflicted destocking trough, so the team gets full marks for execution and honesty, with the bar for the new CEO now set at sustaining growth without the destocking tailwind.

10. Shareholder Friendliness Index

Dividends. Ansell pays an unfranked dividend on a roughly 40% payout policy, so the dividend tracks earnings. Total declared dividends were US45.9¢ for FY23, US38.4¢ for FY24, and US50.2¢ (interim US22.2¢ + final US28.0¢) for FY25. The shape tells the cycle story: the FY23-to-FY24 step down reflects the destocking earnings trough (the payout ratio held, the earnings fell), and the FY25 rebound to a record reflects the recovery. The 1H FY26 interim was lifted to US26.6¢, signalling continued growth. The policy is mechanical rather than generous - investors get a fixed share of earnings, not a progressive dividend.

Buybacks and dilution. This is where Ansell turned more shareholder-friendly. Alongside FY25 results on 25 August 2025, Ansell announced a 10% on-market buyback authorising up to 14,594,488 shares (about 10% of issued capital), valid through 7 September 2026. Execution began around 2 December 2025 with daily ASX disclosures. The MoatMap data shows 20 daily buyback filings in the trailing ~90-day window (since 27 March 2026) totalling about 788,142 shares at prices around AUD 25-30; cumulatively, the company had repurchased roughly 3.4 million shares by early June 2026 - so the program is real and running but still in its early innings relative to the 14.6m authorisation. Before this program Ansell had not been a consistent repurchaser of stock, and option-related issuance kept the share count broadly flat-to-slightly-up; the current buyback is the first material retirement of shares in the window. (Recent ~90-day figures: MoatMap; full authorisation and 3-year context: Ansell FY25 results and ASX buyback announcements, Aug 2025-Jun 2026.)

Verdict: Returns Capital (improving) - a disciplined ~40% dividend plus a genuine, freshly-launched 10% buyback that is actively retiring shares, though the buyback only began in late 2025 so the three-year capital-return record is dominated by a policy-driven dividend that fell and then recovered with the cycle.

11. Insider Activities

Ansell's listing venue is the ASX, where directors file Appendix 3Y "Change of Director's Interest" notices and substantial holders (≥5%) file Forms 603/604/605. The MoatMap database (market: AU) is the spine for this section; for the trailing ~2 weeks I cross-checked the ASX announcement record and found no newer director on-market purchases or sales of note.

Recent transactions (last 12 months):

Buys - read the signal. The only insider-class disclosure in the window is United Super Pty Ltd crossing above the 5% substantial-holder line (Form 603, 2026-05-12). United Super is the trustee of Cbus, a large Australian industry superannuation fund - this is an institutional fund accumulating to an index/active weight, not a director or executive buying with personal conviction. It is a mild positive (a large long-term institution adding to a >5% position), but it carries far less signal than an open-market purchase by the CEO or CFO would. It is not a cluster buy and not management money.

Sells - work out the why. No material insider sells were recorded in the window in the MoatMap data or the recent ASX record.

Net assessment. Insider activity over the last 12 months is sparse and dominated by one institutional substantial-holder notice rather than by director or executive open-market trades. There is no cluster of management buying to flag as bullish, and no insider selling to raise concern. The signal is neutral: a large super fund building a >5% stake is supportive of the float but is not the high-conviction insider-buying signal that would move the needle. The more material capital signal in this window is corporate, not personal - the company itself buying back stock (Section 10) - which is a reasonable proxy for board-level confidence even in the absence of individual director purchases.

12. Scenarios

Bull case. The destocking cycle is firmly behind Ansell, and the company now compounds on a cleaner base. KBU synergies land on schedule from FY26 and beyond, lifting margins in both segments, while KleenGuard and Kimtech deepen Ansell's North American shelf. The Industrial new-product engine keeps producing winners like the Ringers R-840 and the acetone-resistant TouchNTuff, and Life Sciences rides the structural growth of pharma and semiconductor cleanrooms, where switching costs are high and pricing is firm. APIP delivers its full US$50m of productivity, tariffs are absorbed through pricing without volume loss, and the new CEO sustains the discipline of the previous team. The buyback retires a meaningful slice of the share count at sensible prices, and the ~40% dividend grows with earnings. Ansell emerges from the COVID hangover as a higher-margin, more North American, more services-led PPE specialist.

Base case. Ansell delivers roughly what it has guided. Underlying demand stays subdued but positive, organic growth runs in the low-to-mid single digits, and margins grind higher as KBU synergies and APIP savings offset tariff and input-cost headwinds. FY26 adjusted EPS lands inside the guided US137-149¢ band. KBU is fully digested with modest synergy capture, the buyback completes over its authorised window, and the dividend tracks earnings on the 40% payout. The new CEO settles in without a strategic lurch. Nothing breaks, nothing dramatically surprises - a steady, mid-single-digit-growth, margin-improving consumable business that has put its worst cycle behind it.

Bear case. The specific adverse path runs through inventory and tariffs. The inventory Ansell pre-built ahead of US tariffs has to unwind, and if channel partners destock again - or if a weaker industrial economy softens end demand - reported sales whipsaw down just as they did in 2022-2024, with the added sting that there is no further destocking recovery to bail the numbers out. US tariffs on Southeast Asian-made gloves prove stickier and larger than priced, and competitive intensity prevents full price recovery, compressing margin. Commodity glove producers flood the exam/single-use end in another oversupply cycle, dragging Ansell's disposable lines. KBU synergies disappoint or customer attrition from the systems cutover proves worse than disclosed, and the CEO transition adds execution wobble at the worst moment. In this world Ansell is a low-growth, margin-pressured manufacturer whose buyback flatters EPS while underlying earnings stall.